Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT06191796 |
| Title | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Exelixis |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Exelixis Clinical Site #1 | RECRUITING | Orlando | Florida | 32804 | United States | Details |
| Exelixis Clinical Site #3 | RECRUITING | Port Jefferson Station | New York | 11776 | United States | Details |
| Exelixis Clinical Site #2 | RECRUITING | Nashville | Tennessee | 37203 | United States | Details |